HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-01

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

Related Keywords

, Tyrosine Kinase Inhibitors , Unresectable Hepatocellular Carcinoma , Hepatocellular Carcinoma , Hcc , Dotace , Transarterial Chemoembolization , Lenvatinib , Launch Study , Emerald 1 Study , Durvalumab , Bevacizumab , Pembrolizumab ,